Core Insights - Editas Medicine is progressing towards selecting its first in vivo development candidate in September 2025 and aims to file an IND by mid-2026, with human proof-of-concept expected by the end of 2026 [2][3][6] Business Updates - The company presented new preclinical proof-of-concept data for its in vivo programs, demonstrating the potential of its lipid nanoparticle (LNP) platform and gene upregulation strategy [2][3] - Editas has achieved a milestone with the acceptance of the first IND/CTA for its CD19 HD Allo CAR T program in collaboration with Bristol Myers Squibb, marking a significant step in clinical application [6] Financial Performance - For the second quarter of 2025, Editas reported a net loss of $53.2 million, or $0.63 per share, an improvement from a net loss of $67.6 million, or $0.82 per share, in the same period of 2024 [12][15] - Collaboration and other research and development revenues increased to $3.6 million in Q2 2025, compared to $0.5 million in Q2 2024, primarily due to recognized revenue from achieved deliverables [12][15] - Research and development expenses decreased significantly to $16.2 million in Q2 2025 from $54.2 million in Q2 2024, attributed to the discontinuation of the reni-cel program [12][15] Cash Position - As of June 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $178.5 million, down from $269.9 million at the end of 2024, with expectations to fund operations into the second quarter of 2027 [8][16]